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Abstracts / Biol Blood Marrow Transplant 21 (2015) S240eS265 S247hematopoietic stem cell transplantation (HSCT). Fluo-
roquinolones has been recommended for prevention of
bacterial infections in HSCT recipients. Our center has used
oral ciproﬂoxacin and penicillin V, started from beginning of
preparative regimen until engraftment, for bacterial infec-
tion prophylaxis. The objective of this study was to analyze
the prevalence and risk factor of breakthrough bacteremia
during neutropenic episodes in childhood HSCT patients.
There were 215 patients (M:F¼1.26:1) with a median age of
8.32 years (range, 0.51-21.64 years) during 2006-2014. The
common underlying diseases were thalassemia and acute
leukemia. The median day of receiving antibiotic prophylaxis
was 11 days (range, 1-38 days). The most common reason for
discontinuation of antibiotic prophylaxis was febrile
neutropenia (64.5%). Microbiologically documented bacterial
infections were found in 66 patients (30.7%) which 33
patients (15.3%) had bacteremia. Escherichia coli (n¼13) was
the most commonly isolated gram negative bacteria while
Staphylococcus spp. (n¼3) and Streptococcus spp. (n¼3) were
the two most common gram positive bacteria. Risk factor
for bacteremia was receiving ATG-containing regimen (OR
2.67; 95%CI, 1.24-5.77). Other characteristics including age,
diagnosis, preparative regimen, source of stem cells, or
type of donor was not associated with bacteremia. Patients
with bacteremia had a higher rate of mortality compared to
those without bacteremia (36.4% vs 13.3%, p¼0.001). No
serious complication associated with ciproﬂoxacin or
penicillin V was found in this study. In conclusion, this study
demonstrated the feasibility and efﬁcacy of ciproﬂoxacin and
penicillin V prophylaxis in children underwent HSCT.
ATG-containing preparative regimen was the signiﬁcant risk
for bacteremia during neutropenic episodes.339
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Background: Glucocorticoids used to treat acute graft-
versus-host-disease (GVHD) are thought to blunt clinical
symptoms of infection. We set out to address the value of
weekly surveillance blood cultures drawn from patients
receiving high-dose glucocorticoids in the outpatient
department (OPD), and to characterize isolated pathogens,
antibiotic use and outcomes in patients undergoing such
surveillance.
Methods: We conducted a retrospective review of blood
cultures collected from a cohort of hematopoietic cell
transplantation (HCT) patients enrolled in a clinical trial of
GVHD ( grade II) therapy who were treated with high-dose
glucocorticoids (deﬁned as a prednisone dose  0.5 mg/kg/
day). Surveillance blood cultures were deﬁned as those
collected weekly in the OPD while patients were receiving
high-dose glucocorticoids. Cultures obtained as part of a
symptom work-up (e.g. fevers, chills or rigors) or as
follow-up for documented bacteremia were considered
non-surveillance cultures. Clinical data were collected using
center databases supplemented by medical record review.Results: A total of 138 adult HCT recipients were eligible for
inclusion in the study. Patients were excluded from analyses
if they never had surveillance blood cultures (n¼7) or were
inpatient during the study period (n¼4). Of the remaining
127 subjects, 1082 outpatient cultures were obtained, for a
median of 8 cultures (interquartile range [IQR]; 5-10) per
patient; the majority of which were surveillance cultures
(1020 [94%]). Bacteria were isolated from 48 of 1082
cultures (4.4%), or 1 positive culture per 24.5 blood cultures
drawn. Signiﬁcantly fewer surveillance compared to
non-surveillance cultures isolated organisms (41/1020 [4.0%]
vs. 7/82 [8.5%], p¼0.007). The most frequently detected
pathogen was coagulase-negative Staphylococcus (28/1082
[2.7%]). Gram negative rod (GNR) pathogens were rare
(10/1082 [0.9%], 3 Serratia, 2 Enterobacter and 1 Pseudo-
monas, E. coli, Bacteroides, Stenotrophomonas and
Klebsiella), and a similar number GNRs were detected
from surveillance and non-surveillance cultures (p¼0.56).
Antibiotics were administered to nearly all patients with
positive surveillance cultures (38/41 [93%]), and one in 4 was
admitted to the hospital for treatment; none needed ICU care
or died from their infection.
Conclusions: Weekly outpatient surveillance blood cultures
obtained from hematopoietic allograft recipients on high-
dose glucocorticoids were infrequently positive, and the
majority of isolates were low-risk pathogens. Although this
screening approach appeared to have limited value and may
lead to excess antibiotic exposure, future prospective studies
are needed to conﬁrm our ﬁndings in this high-risk
population.340
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Abstract: Patients undergoing hematopoietic stem cell
transplantation or myelosuppressive chemotherapy for solid
and hematologic malignancies have the propensity to
develop thrombocytopenia to the point where they will
require prophylactic platelet transfusions once their level
falls below ten thousand. In our institution, the primary
replacement product is single donor platelets. Recently,
there has been the advent of Acrodose platelets which are
obtained from whole blood. These platelets are leuko-
reduced, ABO matched, pooled and bacteria tested making
them “transfusion ready” for the hospital. It lowers handling
costs at the hospital by eliminating the need for pooling and
bacterial testing at the hospital. The Acrodose system can
detect >1 CFU/ml of bacteria at a rate of 99.3% thus reducing
the risks of false positives. Each unit of Acrodose platelets
contains pools of 4-6 units of leuko-reduced platelet
concentrates in plasma.
Methods: Data was collected from October 2012 to October
2013. Therewere a total of 349 platelet transfusions given, 61
were Acrodose and 288 were single donor. There were 17
bone marrow transplant patients of which 16 were autolo-
gous (7 had multiple myeloma, 8 had Non-Hodgkin’s lym-
phoma and 1 had POEMS syndrome) and 1 was allogeneic for
chronic lymphocytic leukemia. In addition, there were 20
acute leukemia patients. The bone marrow transplant
patients received a total of 45 platelet transfusions of which
37 were single donor and 8 were Acrodose. The acute leu-
kemia patients received a total of 150 platelet transfusions of
which 17 were Acrodose and 133 were single donor.
